1158P - Role of microRNA as biomarkers in small bowel neuroendocrine tumours

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Neuroendocrine Tumours
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Helen Miller
Citation Annals of Oncology (2014) 25 (suppl_4): iv394-iv405. 10.1093/annonc/mdu345
Authors H. Miller1, L. Castellano2, A. Frampton2, E. Stronach2, R. Flora3, J. Stebbing1, A. Frilling2
  • 1Surgery And Cancer, Imperial College London, W12 0HS - London/GB
  • 2Surgery And Cancer, Imperial College London, London/GB
  • 3Department Of Histopathology, Imperial College London, London/GB



Novel molecular biomarkers are needed in neuroendocrine tumours (NET) which can better stratify patients based on factors such as disease aggressiveness and treatment response. Our study was performed on small bowel neuroendocrine tumours (SBNET). Aim 1: determine the global microRNA (miRNA) profile of SBNET. Aim 2: identify miRNA involved in tumour progression for use used as potential biomarkers.


Forty four samples were studied with matched primary/metastasis/normal formalin fixed paraffin embedded tissue from 15 SBNET patients. Included were primary SBNET (n = 15), lymph node metastases (n = 9), adjacent normal small bowel (n = 13) and normal lymph nodes (n = 7). RNA was extracted and 800 miRNA quantified using nCounter® technology (NanoString Technologies, Seattle, USA). Normalisation was performed using the geometric mean of the 100 highest expressed miRNA followed by quantile normalisation. Two-sample t test (p value <0.05, significant) was applied to find significant differentially expressed miRNA between the sample groups.


Out of 800 miRNA, 178 were significantly up or downregulated in SBNET compared to adjacent non-neoplastic tissue. The most up regulated miRNA (-204-5p, -7-5p, -375) and the most downregulated miRNA (-215, -451a -378a-3p, -378i) were chosen for future validation as biomarkers of progression. There were 3 miRNA (-1, -1233, 143-3p) significantly downregulated in lymph node metastasis compared to the primary. One miRNA (-2117) was significantly downregulated in lymph node metastasis compared to normal lymph nodes.


These preliminary results provide information on the global miRNA profile of SBNET and show that some miRNA are differentially regulated during tumour progression. Following further validation, these miRNA have the potential to act as biomarkers for patient stratification based on disease aggressiveness, which could inform patient treatment.


All authors have declared no conflicts of interest.